We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain: Pharmacokinetics of Buccal Mucosa Delivery and Clinical Efficacy.
- Authors
Darwish, Mona; Hamed, Ehab; Messina, John
- Abstract
The treatment of breakthrough pain (BTP), a transitory exacerbation of pain that occurs on a background of otherwise-controlled, persistent pain, requires an opioid formulation and/or method of administration that can provide rapid and extensive systemic exposure. Fentanyl buccal tablet (FBT; FENTORA®, Cephalon, Inc.) employs OraVescent® drug delivery technology, which enhances the rate and extent of fentanyl absorption. OraVescent technology enhances the oral dissolution and buccal absorption of fentanyl, which facilitates rapid uptake of fentanyl into the bloodstream, reducing gastrointestinal absorption and minimizing extensive first-pass metabolism. The resulting pharmacokinetic profile of FBT is characterized by greater bioavailability and a higher early systemic exposure compared with the earlier oral transmucosal fentanyl citrate formulation. In clinical studies of opioid-tolerant patients with cancer-related and noncancerrelated BTP, FBT has provided consistent and clinically relevant improvements in pain intensity and pain relief relative to placebo, with a safety and tolerability profile that is generally typical of that observed with other potent opioids. The pharmacokinetic properties of FBT allow for meaningful clinical efficacy, with an onset of action that closely matches the onset of BTP.
- Subjects
DRUG delivery systems; PAIN management; DRUG therapy; OPIOIDS; FENTANYL; PLACEBOS; METABOLISM; PHARMACOKINETICS; CEPHALON Inc.; PHARMACEUTICAL industry; THERAPEUTICS
- Publication
Perspectives in Medicinal Chemistry, 2010, Issue 4, p11
- ISSN
1177-391X
- Publication type
Article
- DOI
10.4137/PMC.S3928